Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand and voluntarily give informed consent.~2. Male or female patients, age ≥18 years at the time of consent.~3. Diagnosis of hematologic malignancy including, but not limited to, AML, ALL, and MDS. Patients may be newly diagnosed, refractory to initial treatment, or in relapse.~4. Patients with normal renal function, or moderate or severe renal impairment as categorized by creatinine clearance (CrCl)) using the Cockcroft-Gault Formula.~5. Consent of female patients to use a medically acceptable method of contraception for at least 2 months prior to the first dose of CPX-351 and consent of female patients to use a medically acceptable method of contraception throughout the entire study period and for 6 months following the last dose of CPX-351.~6. Male patients must be willing to refrain from sperm donation for 6 months following the last dose of CPX-351and must use adequate contraception throughout the entire study period and for 6 months following the last dose of CPX-351.~Exclusion Criteria:~1. Prior treatment with CPX-351 ≤ to 1 month before the start of CPX-351 in this study.~2. Patients with active (uncontrolled, metastatic) second malignancies are excluded.~3. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent obtaining informed consent.~4. Patients with known hypersensitivity to cytarabine, daunorubicin, or liposomal products.~5. Female patients who are pregnant, nursing, or lactating.~6. Participation in another clinical trial of an investigational drug or medical device within 30 days or 5 half-lives (whichever is longer) prior to enrollment in this study.~7. Any other condition that would cause a risk to patients if they participate in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Normal renal function
- Cohort 2 (Type: EXPERIMENTAL): Moderate renal impairment
- Cohort 3 (Type: EXPERIMENTAL): Severe renal impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).